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The metabolism of vitamin A is a highly regulated 
process that generates essential mediators involved in 
the development, cellular differentiation, immunity, 
and vision of vertebrates. Retinol saturase converts all- 
frans-retinol to all-frans-13,14-dihydroretinol (Moise, 
A. R., Kuksa, V., Imanishi, Y., and Palczewski, K. (2004) 
-/. Biol. Chem. 279, 50230-50242). Here we demonstrate 
that the enzymes involved in oxidation of retinol to ret- 
inoic acid and then to oxidized retinoic acid metabolites 
are also involved in the synthesis and oxidation of all- 
frans-13,14-dihydroretinoic acid. AU-frans-13,14-dihy- 
droretinoic acid can activate retinoic acid receptor/ret­
inoid X receptor heterodimers but not retinoid X 
receptor homodimers in reporter cell assays. AU-frans- 
13,14-dihydroretinoic acid was detected in vivo in 
L ra t—/ — mice supplemented with retinyl palmitate. 
Thus, all-frans-13,14-dihydroretinoic acid is a naturally 
occurring retinoid and a potential ligand for nuclear 
receptors. This new metabolite can also be an interme­
diate in a retinol degradation pathway or it can serve as 
a precursor for the synthesis of bioactive 13,14-dihydro­
retinoid metabolites.
Metabolites of vitamin A (all-iroras-retinol, all-iraras-ROL)1 
play essential roles in vision, immunity, cellular differentia­
tion, control of gene expression, and development in verte­
brates. For example, ll-ws-retinaldehyde (11-cis-RAL) is the 
chromophore of visual pigments in the photoreceptor cells (1),
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whereas all-iroras-retinoic acid (al 1 -trans-RA) and its 9-cis 
isomer are important regulators of gene expression via re ti­
noic acid receptors (RAR) and retinoid X receptors (RXR) (2). 
Other active metabolites of ROL include 14-hydroxy-4,14- 
retro-ROL (3), anhydroretinol (4), and 13,14-dihydroxy-ROL 
(5), which regulate growth and cellular survival. The ring- 
oxidized metabolites 4-oxo-ROL, 4-oxo-RAL, and 4-oxo-RA 
can activate RAR and RXR receptors and have been impli­
cated in the embryonic development of Xenopus (6-8). Bio­
active retinoids continue to be discovered; however, many of 
the enzymes involved in retinoid metabolism have not been 
identified.
The oxidation of ROL is both a major metabolic pathway for 
the synthesis of RAL and RA and a catabolic pathway for the 
clearance of pharmacological doses of ROL by conversion to 
polar metabolites that are easier to secrete (9). The enzymes 
involved in the synthesis and degradation of RA have been 
extensively described. ROL and RAL can be interconverted by 
microsomal short-chain dehydrogenase/reductase (SDR) (10, 
11) and by class I, III, and IV medium-chain alcohol dehydro­
genases (ADH) (12). Irreversible oxidation of RAL to RA is 
carried out by retinal dehydrogenase (RALDH) types 1-4 (13­
18). Cytochrome P450 enzymes CYP26A1, CYP26B1, and 
CYP26C1 carry out the catabolism of RA to 4-hydroxy-RA, 
4-oxo-RA, and 18-hydroxy-RA (19^22).
We recently described a novel enzyme that carries out the 
saturation of the C13_14 bond of all-iroras-ROL to generate 
all-iraras-13,14-dihydro-ROL (all-iraras-DROL) (23). The en­
zyme, ROL saturase (RetSat), is found in many tissues, with 
the highest levels in the liver, kidney, and intestine. RetSat 
was shown to convert all-iraras-ROL to all-iraras-DROL, 
which was detected in several tissues of unsupplemented 
animals (23). Shirley et al. (24) have described the conversion 
of 9-«s-RA to 9-«s-13,14-dihydro-RA (9-cis-DRA) in rats, and 
others have described 9-«s-4-oxo-13,14-dihydroretinoic acid 
as a major metabolite in the liver of mice supplemented with 
ROL palm itate (25). The metabolic pathway responsible for 
the production of 13,14-dihydroretinoids has not been 
investigated.
In the current study, we used lecithin:ROL acyltransferase 
(LRAT)-deficient mice to examine the metabolism of ROL 
palmitate, all-iroras-RA, and all-trans-DROL in vivo, with spe­
cial attention to the formation of C13^ 14-saturated retinoids. 
The pathway was reconstituted in vitro using recombinant 
enzymes and cells transfected with individual retinoid process­
ing enzymes. Finally, we demonstrated that all -trans -DRA can 
activate transcription in reporter cell assays through RAB/RXR 
heterodimers but not RXR homodimers.















Metabolism of Retinoids in Vivo—All animal experiments employed 
procedures approved by the University of Washington and conformed to 
recommendations of the American Veterinary Medical Association 
Panel on Euthanasia and recommendations of the Association of Re­
search for Vision and Ophthalmology. Animals were maintained on a
12-h light and 12-h dark cycle. All manipulations were done under dim 
red or infrared light (>560 nm). Most experiments used 6-12-week-old 
mice. Lrat— /  — mice were genotyped as described previously (26). An­
imals were maintained on a control chow diet up to 1 h prior to oral 
gavage. The appropriate amount of all-irtms-ROL palmitate, all-trans- 
DROL, or all-irtms-RA was dissolved in vegetable oil and administered 
by oral gavage 3 h prior to analysis.
Analysis o f Retinoids—Liver (1 g) from retinoid gavaged or naive 
mice was homogenized in 2 ml of 137 m M  NaCl, 2.7 m M  KC1, and 10 m M  
sodium phosphate (pH 7.4) for 30 s using a Polytron homogenizer. 10 /xl 
of 5 M  NaOH was added to 3 ml of the ethanol ic extract, and the 
nonpolar retinoids were extracted using 5 ml of hexane. The extraction 
was repeated, and the organic phases were combined, dried under 
vacuum, resuspended in hexane, and examined by normal phase HPLC 
using a normal phase column (Beckman Ultrasphere Si 5/x, 4.6 x  250 
mm). The elution condition was an isocratic solvent system of 10% ethyl 
acetate in hexane (v/v) for 25 min at a flow rate of 1.4 ml/min at 20 °C 
with detection at 325 and 290 nm for the detection of nonpolar retinoids 
and 13,14-dihydroretinoids, respectively. The aqueous phase was acid­
ified with 40 /x1 of 12 N HC1, and polar retinoids were extracted with 5 
ml of hexane. The extraction was repeated, and the organic phases of 
the polar retinoid extractions were combined, dried, resuspended in 
solvent composed of 80% CH.CN, 10 m M  ammonium acetate, 1% acetic 
acid, and examined by reverse phase HPLC. Analysis of polar retinoids 
from tissues was done by reverse phase HPLC using a narrowbore, 
120-A, 5-/xm, 2.1 x  250 mm, Denali C18 column (Grace-V.ydac, Hespe­
ria, CA). The solvent system was composed of buffer A, 80% methanol, 
20% 36 m M  ammonium acetate (pH 4.7 adjusted with acetic acid), and 
buffer B, 100% methanol. The HPLC elution conditions were 0.3 ml/ 
min, 100% buffer A for 40 min, 100% buffer B for 10 min, and 10 min 
equilibration in buffer A. The elution profiles of RA and DRA were 
monitored using an online diode array detector set at 350 and 290 nm, 
respectively. The peaks were identified based on their UV-visible spec­
tra  and/or coelution with synthetic or commercially available stand­
ards. The measured area of absorbance was converted to picomoles 
based on a calibration of the HPLC columns using a known amount of 
all-ircms-RA or all-irtms-ROL (Sigma) and all-irtms-DROL or alWra-ns- 
DRA (synthetic standards). The extraction efficiency was monitored by 
spiking a tissue sample with pH]RA (PerkinElmer Life Sciences) and 
monitoring the radioactivity recovered from the HPLC column. In the 
case of liver samples the extraction efficiency was 95% or better. Mass 
spectrometry analyses of synthesized retinoids and of natural retinoids 
purified by HPLC were performed using a Kratos profile HV-3 direct 
probe mass spectrometer.
Synthesis and Analysis of 13,14-Dihydroretinoids—The synthetic 
scheme is depicted in supplemental Fig. 7. fi-1 on one (I) was first bro- 
minated with iV-bromosuccinimide in CC14 followed by substitution of 
bromine with an acetoxyl group in hexamethylphosphoramide. The 
acetate ester of ionone was hydrolyzed with K2C03 in methanol:water, 
and then the hydroxyl group was protected with fe<ra-butyldimethylsi- 
lyl group. The silylated 4-hydroxy-f!-ionone (II) was then condensed 
under Horner-Emmons conditions with triethylphosphonoacetate, and 
the ester of silyl-protected ethyl 4-hydroxy-f!-ionylidene acetate was 
reduced to alcohol with LiAlH4. The alcohol was acetylated with acetic 
anhydride in the presence of iV.iV-dimethylaminopyridine (DMAP); the 
silyl group was removed by tetrabutylammonium fluoride, and the 
alcohol was oxidized to a ketone group with M n02 to give 15-acetoxy- 
4-oxo-f!-ionylidene ethanol (III). Next, ester (III) was hydrolyzed, and 
the hydroxyl group was brominated with PBr„ in ether. The bromide 
was reacted with PPh3 to give Wittig salt (IV), which was further 
condensed with ethyl 4-oxo-3-methylbutyrate under conditions de­
scribed previously (23) to obtain a mixture of ethyl 13,14-dihydro-4- 
oxoretinoate isomers (V) with all-trans- as a major compound. The 
isomers were separated by normal phase HPLC (HP1100, Beckman 
Ultrasphere Si 5/x, 10 x  250 mm, 5% ethyl acetate:hexane, and detec­
tion at 325 nm) and characterized by their UV, mass, and NMR spectra. 
NMR data were recorded on a Broker 500-MHz spectrometer using 
CDCL as an internal standard, and their chemical shift values are 
listed in supplemental Table II. The order of elution was as follows: 
9,11 -di-W.s*-, alWra-ns-, 9-cis, ll-c;'s-13,14-dihydro-4-oxoretinoate. To ob­
tain free retinoic acid (VI), the ethyl ester was hydrolyzed with NaOH
in ethanol:H20 . To obtain 13,14-dihydro-RAL (DRAL), previously pre­
pared ethyl 13,14-dihydroretinoate was reduced with diisobutyl alumi­
num hydride at -7 8  °C. All-ir(ms-4-oxo-DRA has the following UV- 
visible absorbance spectrum in ethanol, Amnx = 328 nm and shoulder at 
A = 256 nm, and in hexane, Amnx = 314 nm and shoulder at A = 252 nm.
Cloning and Expression Constructs—Total embryo and liver RNA 
was obtained from Ambion (Austin, TX) and reverse-transcribed using 
SuperScript II reverse transcriptase (Invitrogen) and oligo(dT) primers 
according to manufacturer’s protocol. Embryo cDNA was used to 
amplify the cDNAs of specific genes using Hotstart Turbo Pfu 
polymerase (Stratagene, La Jolla, CA) and the following primers: RA­
LDH 1, forward 5'-CACCGCAATGTCTTCGCCTGCACAAC and reverse 
5'-GCTGGCTTCTTTAGGAGTTCTTC; RALDH3 forward CACCTGCG- 
AACCAGTTATGGCTACC and reverse 5'-GCCTGTTCCTCAGGGGTT- 
CTT; CYP26B1, forward 5'-CACCAAGCGGCTGCCAACATGC and re­
verse 5'-GCTGAGACCAGAGTGAGGCTA; and CYP26C1 forward 5'-C- 
ACCCATTCTCGCCATGATTTCCT and reverse S'-CCAAGGCTAGAG- 
AAGCAACG. The full-length cDNA of RALDH2 (MGC:76772, IMAGE: 
30471325), RALDH4 (MGC:46977, IMAGE:4223059), and CYP26A1 
(MGC: 13860, IMAGE:4210893) mRNA was obtained from the Mamm­
alian Gene Collection (MGC). These clones were used as templates to 
amplify the respective cDNAs using Hotstart Turbo Pfu polymerase 
(Stratagene) and the following primers: RALDH2, forward 5'-CACCA- 
TGGCCTCGCTGCAGCTCCTGC and reverse 5'-GGAGTTCTTCTGGG- 
GGATCTTCA; RALDH4, forward 5'-CACCTGTACACAGAGGGCACT- 
TTCC and reverse 5'-GTATTTAATGGTAATGGTTTTTATTTCAGTA- 
AAG; and CYP26A1, forward 5' -C AC C ATGGGGCTC CC GGC GCTGCT 
and 5'-GATATCTCCCTGGAAGTGGGTAAAT. The cDNAs for RAL- 
DH1, -2, -3, and -4 and CYP26A1, -Bl, and -Cl were cloned in the 
pcDNA3.1 Directional TOPO vector under the control of the CMV 
promoter to express a recombinant protein fused with a C-terminal V5 
epitope peptide (GKPIPNPLLGLDST) and a His„ tag (Invitrogen). Both 
strands of the expression constructs were sequenced to ensure no mu­
tations were present.
Mouse RXR-« was cloned using the primers 5'-GGGCATGAGT- 
TAGTCGCAGA and 5'-AGCTGAGCAGCTGTGTCCA from reverse- 
transcribed mouse liver cDNA. The RXR-r, open reading frame was 
then subcloned into the pcDNA3.1 Directional TOPO vector (Invitro­
gen) using the primers 5'-CACCATGGACACCAAACATTTCCT and 5'- 
AGCTGAGCAGCTGTGTCCA under the control of the CMV promoter. 
The RXRE from the vector RXR (2) translucent reporter vector (Panom- 
ics, Redwood City, CA) was amplified using the primers 5'-CTCAAC- 
CCTATCTCGGTCTATTCT and 5'-ATGCCAGCTTCATTATATACCCA 
and cloned upstream of the minimal promoter and f!-galactosidase open 
reading frame of pBLUE-TOPO (Invitrogen) to create the pRXRE- 
BLUE expression construct. This construct places five consecutive DR1 
elements upstream of f!-galactosidase, the expression of which becomes 
dependent on activation of RXR and formation of RXR homodimers. 
Both strands of all constructs were sequenced to ensure no mutations 
were present.
Oxida tion of All-trans-ROL and All-trans-DROL Using Liver Alcohol 
Dehydrogenase—Equine liver ADH (EC 1.1.1.1) was obtained from 
Sigma and dissolved in 50 m M  Tris (pH 8.8) to a concentration of 5 
units/ml (8.6 mg/ml). NAD and NADP were mixed together (1:1) at a 
concentration of 10 m M  each. A substrate solution, 2 /xl of 2 m M  stock of 
all-ircms-ROL or all-irtms-DROL in iV,iV-dimethylformamide, was 
added to a 1.5-ml Eppendorf tube containing 20 ju,l of 10% bovine serum 
albumin, 20 /xl of ADH, 2 /xl of cofactor mixture, and 50 m M  Tris (pH 8.8) 
to a total volume of 200 /xl. The solutions were incubated at 37 °C for 60 
min, after which 50 /xl of 0.8 M  NH20H  solution (pH 7.0) was added, 
followed by addition of300 /xl of methanol, 15 min at room temperature, 
and extraction with 300 /xl of hexane. The organic phase was dried and 
analyzed by normal phase HPLC as described in the analysis of non­
polar retinoids extracted from tissue samples. As a control for the 
nonenzymatic reaction, boiled protein (90 °C for 5 min) was used with or 
without addition of cofactors.
RALDH Oxidation Assay—iV-Acetylglucosaminyltransferase I-nega- 
tive HEK-293S cells, obtained from Dr. G. Khorana (Massachusetts 
Institute of Technology, Boston) (27) were cultured in Dulbecco’s mod­
ified Eagle’s medium, 10% fetal calf serum and maintained at 37 °C, 5% 
C 02, and 100% humidity. For RALDH enzyme assays, cells were tran ­
siently transfected with RALDH1, -2, -3, or -4 expression constructs 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. After 48 h post-transfection, the cells were collected by scrap­
ing and were centrifuged. The cell pellet was washed in 137 m M  NaCl, 
2.7 m M  KC1, and 10 m M  phosphate (pH 7.4), resuspended in 50 m M  Tris 
(pH 8.0) containing 250 m M  sucrose, and homogenized with the aid of a 














niM NAD, 5 niM NADP, and t niM ATP. An aliquot of the cell lysate was 
boiled for 10 min at 95 °C to provide the control for the nonenzymatic 
reaction. Substrates in the form of all-trans-RAL or a mixture of iso­
mers of DRAL were added to the cell lysates at a final concentration of 
60 /LiM. The reactions were allowed to proceed for 2 h a t 37 °C with 
shaking and were stopped by the addition of 2 volumes of CH3CN. 
Samples were treated for 30 min at room temperature with 100 mM 
NH20H  (final concentration from a freshly made stock of 1 M (pH 7.0)) 
followed by centrifugation a t 12,000 x  g  for 10 min. The clear super­
natant was acidified with 0.1 volume of 0.5 M ammonium acetate (pH 
4.0) and examined by reverse phase HPLC system (Zorbax ODS, 5 /Lim, 
4.6 x  250 mm: Agilent, Foster City, CA) with an isocratic mobile phase 
A of 80% CH3CN, 10 m M  ammonium acetate, 1% acetic acid, and a flow 
rate of 1.6 ml/min held for 15 min. After each run, the column was 
washed with mixture B (60% tot-butyl methyl ether, 40% methanol) for 
10 min at 1.6 ml/min, followed by re-equilibration in phase A. The 
elution of RA and DRA isomers was monitored at 340 and 290 nm, 
respectively. The peaks were identified based on their spectra and 
coelution with standards. The cell lysate was examined for expression of 
RALDH1--4 by SDS-PAGE and immunoblotting of the V5 epitope- 
tagged recombinant protein using an anti-V5 epitope monoclonal anti­
body (Invitrogen).
CYP26A1 Oxidation Assay—JV-Acetylglucosaminyltransferase I- 
negative HEK-293S cells were transiently transfected with cDNAs of 
CYP26A1, -Bl, and -Cl under the control of CMV promoter using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s pro­
tocol. After 24 h, the transfected cells were split into 12-well plates to 
ensure an equal number of transfected cells in each assay well. 
All-f/'crns-RA or all-f/'crns-DRA was added to the cell monolayer a t 0.1 
m M  final concentration in complete media and incubated for 4 h. 
Media and cells were collected by scraping, and proteins were pre­
cipitated with an equal amount of CH3CN by vigorous vortexing 
followed by centrifugation a t 12,000 x  g  for 10 min. For RA analysis 
the clear supernatant was acidified with 0.1 volume of 0.5 M ammo­
nium acetate (pH 4.0) and examined by reverse phase HPLC as 
described for the RALDH assays. The elution of all-trans-RA, all- 
f/'crns-DRA, and their oxidized metabolites was monitored a t 340 and 
290 nm. The peaks were identified based on their spectra and coelu­
tion with standards. The cell lysate was examined for expression of 
CYP26A1, -Bl, and -Cl by SDS-PAGE and immunoblotting of the V5 
epitope-tagged recombinant protein using an anti-V5 epitope mono­
clonal antibody (Invitrogen).
Conversion o f DltOL to DRA in RPE—UV-treated RPE microsomes 
were prepared as described previously (28). Twenty jLil of UV-treated 
RPE microsomes (3 mg/ml) were mixed with 20 /lim DROL or ROL 
substrates, 1% bovine serum albumin, and 50 m M  Tris (pH 8.8) and 
were incubated at 37 °C for 60 min in the presence or absence of NAD 
NADP cofactor mixture at 50 /lim each. In order to stop the reaction, 
proteins were precipitated by mixing with an equal volume of CH3CN 
followed by high speed centrifugation. The clear supernatant was acid­
ified with 0.1 volume of 0.5 M ammonium acetate (pH 4.0) and examined 
by reverse phase HPLC as described for the RALDH assays. A boiled 
RPE membrane control was used to assay nonenzymatic conversion of 
DROL. The elution of all-irans-DROL metabolites was monitored at 
290 nm.
RARE and RXRE Activation Assay—The RARE reporter cell line 
F9-RARE-lacZ (SIL15-RA) was a kind gift from Dr. Michael Wagner 
(State University of New York Downstate Medical Center) and Dr. 
Peter McCaffery (University of Massachusetts Medical School, E. K. 
Shriver Center). The RA-responsive F9 cell line was transfected with 
a reporter construct of an RARE derived from the human retinoic acid 
receptor-^ gene (RARfi) placed upstream of the Escherichia coli lacZ 
gene (29). Cells were grown in L15-C02 media containing N-3 sup­
plements and antibiotics. Cells were stimulated for 24 h in the dark 
a t 37 °C and 100% humidity with all-trans-RA or all-trans-DRA dis­
solved in ethanol a t the indicated concentrations, lysed, and assayed 
for the expression of £>-galactosidase using the £>-galactosidase en­
zyme assay system (Promega, Madison WI). For RXRE activation 
assays JV-acetylglucosaminyltransferase I-negative HEK-293S cells 
were transfected with the pRXRE-BLUE reporter construct with or 
without the RXRa-expression construct using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. After 24 h, cells 
were split into 24-well plates to ensure an equal number of trans­
fected cells in each assay well. Cells were stimulated with appropri­
ate concentrations of all-trans-RA, 9-cis-RA, or all-trans-DRA. After 
48 h, the expression of £>-galactosidase was assayed as described 
above.
RESULTS
Identification o f All-trans-DROL and Its Metabolites in the 
Liver o f Lrat—/ — Mice Gavaged with All-trans-ROL Palmi- 
tate—ROL absorption in mammals is an active process driven 
by esterification and hydrolysis cycles. Esterification of ROL is 
carried out mainly by the LRAT enzyme (30). In the absence of 
LRAT, the equilibrium between ROL and ROL esters is shifted 
in favor of free ROL. Mice deficient in LRAT expression 
(L ra t- /- )  mice are severely impaired in their ROL uptake and 
storage capacity (26). Wild type mice, on the other hand, con­
vert most of the ingested ROL to esters, which sequester ROL 
from circulation and metabolism. Thus, we chose to study the 
saturation and oxidation of all-ftwis-ROL to 13,14-dihydroreti­
noid metabolites in L r a t - / -  mice.
Given their similar chemical properties, it is not surprising 
that all-ircms-DROL and all-ircms-ROL follow parallel meta­
bolic pathways. Two different groups of L r a t- / -  mice were 
dosed with either 106 units of all-ircms-ROL palmitate/kg body 
weight or 105 units of all-ircms-ROL palmitate/kg body weight, 
and their livers were examined for polar and nonpolar retinoid 
metabolites at 3 h post-gavage. Reverse phase HPLC analysis 
of polar hepatic retinoids indicated the presence of all-ircms-RA 
(Fig. 1, A and B, peak 5) and all-ircms-DRA (Fig. 1, A and B, 
peak 4), as well as a cis-DRA isomer (Fig. 1, A and B, peak 2). 
We also observed another polar DROL metabolite, which eluted 
earlier than all-ircms-DRA, on reverse phase HPLC (Fig. 1, A 
and B, peak 1) and had the same absorbance spectrum as 
all-ircms-DRA standard (Fig. IE). This metabolite was not 
chemically characterized; however, based on its polar charac­
ter, it could represent a taurine or glucuronide DRA conjugate. 
The spectra and elution profiles of synthetic all-iraras-DRA and 
all-ircms-DRA isolated from liver matched (Fig. IE). All-trans- 
DRA was synthesized according to procedures published pre­
viously (23) and was characterized by 1H NMR (supplemental 
Table II).
We examined the nonpolar hepatic retinoid metabolites by 
normal phase HPLC. At 3 h post-gavage with ROL palmitate, 
the livers of the examined mice contained high levels of all- 
ftwis-ROL (Fig. 1, C and D, peak 11), whereas all-ircms-DROL 
(Fig. 1, C and D, peak 8) was found at 280 ^ 330-fold lower levels 
(Table I). The absorbance spectra and elution profile of all- 
ftwis-DROL matched the synthetic standard prepared accord­
ing to published procedures (23) and characterized by 1H NMR 
(Fig. 1, C, D, and G, and supplemental Table II).
Another nonpolar 13,14-dihydroretinoid metabolite (Fig. 1, C 
and D, peak 6) that was present at higher levels than DROL 
was identified in the liver of mice gavaged with all-ircms-ROL 
palmitate. The spectra of this compound also matched that of 
all-ftwis-DROL (Fig. IG). The compound does not coelute with 
«s-DROL isomers and has a different UV-visible absorbance 
maximum than «s-DROL isomers (not shown). We were able to 
esterify the compound, whereas NH2OH treatm ent had no 
effect on its elution profile (not shown). Thus, we conclude that 
the functional group of the compound eluting as peak 6 (Fig. 1, 
C and D) is alcohol. Electron-impact mass spectrometry anal­
ysis of the collected fraction corresponding to peak 6 indicates 
the presence of a compound with an m /z  of 274 (Fig. IF). This 
suggests that peak 6 could include the chain-shortened C19- 
ROL derivative (C19H30O, m /z  =  274, depicted in Scheme 1).
Following gavage of L r a t- / -  mice with synthetic all-trans- 
DROL, we observed significant levels of all-ircms-DRA and 
all-ircms-4-oxo-DRA. These were identified based on their chro­
matographic profile, m /z, and absorbance spectra, which 
matched those of synthetic standards (supplemental Fig. 8A 
and inset spectra). All-ircms-4-oxo-DRA was synthesized ac­













ac Fig. t. Analysis o f metabolism of all-fr««s-ROL palm itate in  the liver of L ra t—I— mice. A D . HPLC analysis of the polar and nonpolar retinoids from the liver of Lrat- /  -  mice gavaged with alWra/is-ROL palmitate. Mice were gavaged with alWra/is-ROL palmitate at a high dose 
of tO6 units/kg body weight (marked as 10XRP, n = 3) in A  and C or with a lower dose of alWra/is-ROL palmitate of 10“ units/kg body weight 
(marked as 1XRP, n = 3) in B and D. Three h after gavage, the polar and nonpolar retinoids from liver were extracted. The retinoids were analyzed 
by reverse phase HPLC on a narrowbore column system CA and Bj, and the nonpolar retinoids were analyzed by normal phase HPLC (C and D). 
Compounds were identified based on comparison with the elution profile and absorbance spectra of authentic standards. E, the spectrum of peak 
4 matches that of all-ira«s-DRA standard, with which it coelutes. The absorbance spectrum of another compound, peak 1, eluting earlier than 
all-ira«s-DRA by reverse phase HPLC, also matches tha t of all-ira«s-DRA. F, the electron impact mass spectrometry analysis of the compound 
eluting as peak 6 in C and D indicates it is a possible mixture of compounds with ink  of 274 and 260. G, the compound eluting as peak 6 exhibits 
a UV-visible absorbance profile identical to the one of biological all-ira«s-DROL (peak 8) and of synthetic all-ira«s-DROL. Elution of all-ira«s-RA 
was monitored a t 350 nm, alWra/is-ROL a t 325 nm, and all-ira«s-DROL and all-ira«s-DRA a t 290 nm. Only the absorbance a t 290 nm is shown 
here for simplicity. The extraction efficiency was >95% and was calculated based on spiking samples with pHJRA and measuring the radioactivity 
associated with the RA peak. Based on elution time, absorbance spectra, and comparison with authentic standards, the peaks were identified as 
the following compounds: peak 2, c;'s-DRA; peak 3, 13-c;'s-RA; peak 4, all-ira«s-DRA; peak 5, all-ira«s-RA; peak 6, C19-ROL derivative; peak 7,
13-c/s-ROL; peak 8, all-ira«s-DROL; peak 9, 9,13-di-c;'s-ROL; peak 10, 9-c;'s-ROL; and peak 11, all-ira/is-ROL.
Table I
Level o f liver retinoids 3 h following gavage with ROL palmitate 
The analysis was carried out as described under “Materials and 
Methods."
Compound identified
106 IU/kg body 
weight-dose 
level of all-trans- 
ROL palmitate
105 IU/kg body 
weight-dose 
level of sM-trans- 
ROL palmitate
pmolig tissue
All-£ra/is-RA 9,400 ± 300 320 ± 240
All-£ra/is-DRA 190 ± 17 10 ± 2
cis-DRA 180 ± 53 22 ± 4
Fig. 1, A  and B, peak I 460 ± 50 37 ± 9
All-£ra72s-ROL 28,000 ± 300 7,000 ± 1,200
Al\-trans-DROL 100 ± 18 21 ± 4
Fig. 1, C and D, peak 6 1,800 ± 370 200 ± 8
characterized by 1H NMR (supplemental Table II). The livers of 
mice gavaged with DROL were also found to contain low levels 
of C19-ROL (supplemental Fig. 8B, peak 4, and inset spectrum).
This is in contrast to the high levels of C19-ROL observed in 
all-iroras-ROL palmitate gavaged mice.
It has been reported that rats can convert exogenously ad­
ministered 9-ds-RA to 9-ds-DRA and its taurine conjugate 
(24). We have shown that RetSat does not saturate all- 
trans-RA (23) or 9-ds-RA.2 This would suggest that another 
pathway is responsible for saturation of the C13_14 bond of RA 
to produce DRA. In the current study, we found no evidence of 
all-iraras-DRA or all-iroras-4-oxo-DRA formation in the livers of 
Lrat—/— mice gavaged with all-iroras-RA at 3 h post-gavage 
(supplemental Fig. 9). A compound different from all-trans - 
DRA (supplemental Fig. 9, marked with *) with a maximum 
absorbance of257 nm eluted before the expected elution time of 
all-irons-DRA. This would suggest that 13,14-dihydroretinoid 
metabolites can only be derived from all-iro ns-DROL after 
saturation of all-iroras-ROL by RetSat, emphasizing the key














Schem e 1. Metabolism of all-trans-liOL and all-frans-DROL. R etS a t s a tu ra te s  all-ft'ons-ROL to all-ft'ons-D ROL, w hich  w as previously  
show n to  be esterified  by LRAT. H ere  we p resen t evidence d em o n s tra tin g  th a t  th e  oxidative m etabo lism  of DROL closely follows th a t  of ROL. Broad 
spectrum  enzym es such  as SDR an d  ADH carry  o u t th e  reversib le  ox idation  of all-irons-D R O L to all-ft'ons-DRAL. RALDH 1. -2, -3. an d  -4 oxidize 
all-ft'ons-DRAL to  all-ft-ans-DRA. Several m em bers of th e  cytochrom e P450 enzym es CYP26A1. -B l. an d  -C l oxidize all-ft-ans-DRA to  a ll-trans- 
4-oxo-DRA, iden tified  in vivo  an d  in vitro. O th er oxidized all-i?'«?i6-DRA m etabo lites, w hich  a re  no t depicted, could be all-i?'«?i6--4-hydroxy-DRA, 
all-i?'o?j6-5.6-epoxy-DRA. all-i?'«?i6--5.8-epoxy-DRA, and  all-i?'«?i6-18-hydroxy-DRA. T he sh o rt-chain  m etabo lite  C19-ROL is show n h e re  w ith  its  
possible chem ical s tru c tu re . I ts  syn the tic  p a th w ay  m ay  proceed from  e ith e r  all-i?'«?i6--RA by decarboxylation  and/or from  all-i?'«?i6-DRA via 
Q-oxidation.
role played by RetSat at this branch of vitamin A metabolism. 
We also found no evidence of C19-ROL in the livers of Lrat—/— 
mice gavaged with all-frares-RA at 3 h post-gavage (not shown).
The levels of all-frans-RA, all-frans-DRA, and the com­
pounds eluting as peak 1 in Fig. 1, A  and B, and as peak 6 in 
C and D, are indicated in Table I and reflect the different 
starting levels of ingested ROL palmitate. The levels of all- 
frans-DRA are much lower (30^50-fold) than those of all- 
trans-RA, which could indicate tha t saturation by RetSat is a 
limiting step. The low levels of all-frans-DROL in comparison 
with all-frans-ROL also support this explanation. The levels 
of all-frans-DROL and all-frans-DRA may also be low be­
cause of further processing to shorter chain or to other more 
oxidized metabolites.
Characterization of the Metabolic Pathway of All-trans- 
DROL to All-trans-DRA—Given that all-frans-DRA is detected 
in vivo as a metabolite of all-frans-DROL, we decided to exam­
ine its possible mode of synthesis using reconstituted enzyme 
systems. To oxidize all-frans-DROL to the corresponding alde­
hyde all-frans-DRAL, we used ADH purified from horse liver 
(EC 1.1.1.1), which is active toward both primary and second­
ary alcohols. All-frares-DROL and all-frans-ROL were incu­
bated with purified enzyme and the appropriate cofactors. Fol­
lowing the reaction the samples were treated with NH2OH, 
extracted into the organic phase, and examined by normal 
phase HPLC. All-frans-RAL or all-frans-DRAL oximes were 
identified by comparison with synthetic standards (23). ADH 
efficiently carried out the conversion of all-frans-ROL to all- 
trans-RAL and of all-frans-DROL to all-frans-DRAL in the 
presence of NAD and NADP cofactors (Fig. 2, A and B) and not 
in their absence (not shown). The boiled enzyme did not exhibit 
any activity toward either substrate. Next, photoreceptor-spe­
cific RDH (prRDH) and RDH12 were tested for ability to cata­
lyze the oxidation of all-frans-DROL to all-frans-DRAL. Both 































F i g ,  2 , Oxidation of all-£rons-ROL and all-£rarcs-DROL to the 
respective aldehyde. Purified ADH (Sigma) catalyzed the oxidation 
ofalUrcms-DROL to all-ftww-DRAL (A) and all-frans-ROL to alUrans- 
RAL (B) in the presence of NAD and NADP. Control reactions using 
boiled enzyme were negative and show that the conversion is enzy­
matic. Retinoids were extracted and analyzed by normal phase HPLC. 
The products of the reaction were syn- and <m£j-all-£r<ms-DRAL oximes 
(A) and syn- and anti-&\\-trans-RKL oximes CB). The experiment was 














Fig. 3. Oxidation of all/rans-RAL and all/rans-DRAL to all/rans-RA and all/rans-DRA, respectively. Cells were transiently transfected 
with vector carrying the cDNA of RALDH2 fused at its C terminus to a V5-His6 tag. The expression of RALDH2-V5-His6-tagged protein was confirmed 
by immunoblotting with anti-V5 monoclonal antibody and is shown in the top panel on the right in the lane labeled Raldh2, Cell homogenates of 
transfected HEK-RALDH2 cells (black solid line graph) or untransfected control cells (gray solid line graph) were incubated with all-irans-RAL (A) or 
all-irans-DRAL IB). Boiled control cells (black dashed line graph) were incubated with substrates under the same conditions. Retinoids were extracted 
and analyzed by reverse phase HPLC as described under “Methods and Materials.” The products of the reaction were identified based on their 
absorbance spectra and coelution with available standards. These are as follows: peak 1, all-irans-RA; peaks 2 and 3, syn- and anti-KAL oxime, 
respectively; peaks 4 and 5, eis-isomers of DRA; peak 6, all-irans-DRA; peaks 7-10, syn- and emft'-oximes of several isomers of DRAL; peak 11, 
all-irans-DROL. The UV-visible absorbance spectra of peak 1 (identified as RA) and peak 6 (identified as DRA) are shown in middle and bottom- panels 
on the light, respectively. The experiment was performed in duplicate and repeated three times. Similar results were obtained with cells transfected 
with RALDH3 tagged at the C terminus with V5-His„ tag.
all-fraras-RAL but much less so in converting all-fraras-DROL to 
all-fraras-DRAL (results not shown).
Conversion of all-fraras-DRAL to DRA is mediated by 
RALDH enzymes. Mouse RALDH1-4 cDNAs were cloned and 
fused at their C terminus with a tag containing a V5 epitope 
and His6 stretch. Glycosylation-deficient HEK-293S cells were 
transiently transfected with the tagged constructs of RALDH1, 
-2, -3, or -4 under the control of the CMV promoter. These cells 
allow the reproducible, high level expression of recombinant 
proteins (27). The cell homogenate of transfected cells was 
supplemented with NAD, NADP, and ATP cofactors and with 
all-fraras-RAL or all-fro ras-DRAL substrates. RALDH2 and -3 
both efficiently converted all-froras-RAL and all-froras-DRAL 
into all-froras-RA and all-froras-DRA, respectively (Fig. 3, A and 
B). The products all-froras-RA and all-froras-DRA were identi­
fied based on their elution time, absorbance spectra, and com­
parison with authentic standards (Fig. 3A, peak 1, and B, peak
6, and inset spectra). Other cis-DRA isomers were also pro­
duced as a result of oxidation of cis-DRAL isomers present in 
the synthetic mixture. The expression level of recombinant 
protein in transfected cell homogenate was verified by immu­
noblotting using anti-V5 monoclonal antibody for the presence 
of V5-tagged RALDH protein. This is shown for RALDH2-V5- 
His6 in Fig. 3 (top right panel). Based on the intensity of the 
immunoreactive band, similar expression levels of RALDH1, 
-2, -3, or -4 were attained in transfected cells (not shown). 
Homogenates of RALDH1- and RALDH4-transfected cells were 
less efficient in oxidizing all-froras-RAL or all-froras-DRAL, pos­
sibly a consequence of the C-terminal tag affecting some 














Fig. 4. Oxidation o f all-£raras-BA and all-traras-DRA. The metabolism of RA and DRA was examined in untransfected cells or cells 
transfected with CYP26A1. The expression of CYP26Al-V5-His6-tagged protein in transfected cells was examined by SDS-PAGE and immuno­
blotting with anti-V5 monoclonal antibody and is shown in the top panel on the right in the lane labeled Cyp26Al. Transfected HEK-CYP26A1 cells 
(black dashed line graph) or untransfected control cells (gray solid line graph) were incubated with RA (A) or DRA (B). Retinoids were extracted 
and analyzed by reverse phase HPLC as described under “Materials and Methods." The spectra of oxidized RA metabolites, peaks 1 and 2 (right 
top inset panel), resemble those of all-irafis-4-hydroxy-RA and all - / r  r; / ;.s* - - oxo -RA, respectively. Peaks 3-5  are c/s-isomers of RA; peak 6 is 
all-irans-RA. Peaks 7 and 9 represent oxidized DRA metabolites and have a Anmx = 290 nm shown in the middle inset panel on the right. Peak 8 
corresponds to all-irafis-4-oxo-DRA based on its absorbance spectra and elution time (absorbance spectra shown in lower inset panel on the right). 
Peaks 10 and 7 7 represent cis- and all-irans-DRA, respectively. The experiment was performed in duplicate and repeated three times. Similar 
results were obtained with cells transfected with CYP26B1 and -Cl.
be more active than others, as seen for mouse RALDH2 (Km = 
0.66 /xm for all-iraras-RAL) versus mouse RALDH1 (Km = 11.6 
/xm for all-iraras-RAL) (31, 32). Untransfected cells also exhib­
ited significant activity toward both all-iraras-RAL and all- 
iraras-DRAL (Fig. 3, gray line, chromatogram), suggesting en­
dogenous RALDH activity in HEK-293S cells.
Oxidation o f AIJ-trans-DRA—The level of RA is tightly 
controlled by both spatially and temporally regulated synthe­
sis and degradation. RA catabolism is carried out by cyto­
chrome P450 enzymes CYP26A1, -Bl, and -Cl. I t is impor­
tan t to determine whether DRA could also be catabolized in a 
similar manner. HEK-293S cells were transfected with ex­
pression constructs of CYP26A1, -Bl, and -Cl fused at their 
C termini with a V5 epitope and Hisa stretch. Transfected 
and untransfected cells were incubated with all-iraras-RA or 
all-iraras-DRA substrate in culture because CYP26A1, -Bl, 
and -Cl activity was adversely affected by homogenization of 
cells. Oxidized metabolites of all-iroras-RA and all-iroras-DRA
were present in CYP26Al-transfected cells but not in un­
transfected cells (Fig. 4, A  and B). These metabolites, which 
could include all-iroras-4-oxo-(D)RA, all-iroras-4-hydroxy- 
(D)RA, all-iraras-5,8-epoxy-(D)RA, and all-iroras-18-hydroxy- 
(D)RA, were identified as polar compounds eluting shortly 
after the injection spike (Fig. 4, A  and B, peaks 1 and 2 and 
peaks 7-9, and inset spectra). One of the oxidized all-trans- 
DRA compounds was identified as all-iraras-4-oxo-DRA be­
cause it matched the elution profile and absorbance spectrum 
of a synthetic standard (Fig. 4, lower right, inset panel). The 
level of tagged enzyme expressed in transfected cells was 
assayed by SDS-PAGE analysis of transfected cell lysates, 
followed by immunoblotting using an anti-V5-monoclonal an­
tibody (Fig. 4, top right panel). The level of expression of 
CYP26A1, -Bl, and -Cl in transfected cells was similar, and 
all three enzymes efficiently carried out the oxidation of 
















Fig. 5. Response of F9-RARE-ZaeZ reporter cell line to RA and DRA. F9-RARE-/acZ cells express endogenous RAR and RXR and were 
transfected with a construct of lacZ under the control of a minimal promoter and upstream DR5 elements (29). F9-RARE-/acZ cells were treated 
with different doses of all-irans-RA or all-irans-DRA for 24 h. The RARE-driven lacZ gene produces (3-galactosidase, which hydrolyzes X-gal to an 
insoluble blue product, which was visualized in responder cells by light microscopy (top panels). Alternatively, the response of the cell population 
was quantified by measuring the f!-galactosidase activity using the substrate o-nitrophenyl (3-n-galactopyranoside. The colorless substrate was 
hydrolyzed by f!-galactosidase to soluble, yellow-colored o-nitrophenol, whose absorbance was measured at 420 nm using a spectrophotometer 
(bottom, bar graph). The background f!-galactosidase activity in unstimulated cells is indicated by dashed line. The experiment was repeated twice 
with similar results.
Conversion o f All-trans-DROL to All-trans-DRA in RPE— 
Retinoid metabolism occurs in many embryonic and adult tis­
sues. Thus, it is important to determine whether the entire path­
way of synthesis of all-irans-DRA can be reconstituted with 
tissue extracts. All-irans-DROL (supplemental Fig. 10, peak 2) 
was efficiently converted to all-irans-DRA (supplemental Fig. 10, 
peak 1) by microsomes prepared from RPE cells in the presence of 
dinucleotide cofactors NAD and NADP. All-irans-DRA was iden­
tified based on its elution profile and absorbance spectrum in 
comparison with synthetic all-irans-DRA (supplemental Fig. 10 
and inset spectra). RPE microsomes also catalyzed the conversion 
of all-irans-ROL into all-irans-RA (results not shown), which 
indicates that adult RPE could be an active all-irans-RA, all- 
irans-DRA synthesis site. The main ROL oxidizing activity in the 
RPE is catalyzed by SDR family enzymes. The efficient conver­
sion of all-irans-DROL to all-irans-DRA in the RPE supports the 
existence of SDR enzymes that can convert all-irans-DROL into 
all-irans-DRAL. Further studies are required to examine the 
substrate specificity of the known SDR enzymes from the RPE 
with respect to all-irans-DROL.
Based on the known all-irans-ROL oxidation pathway and 
results presented here, we propose that following saturation of 
all-irans-ROL to all-irans-DROL, all-irans-DROL is oxidized to 
all-irans-DRA and later to all-irans-4-oxo-DRA and possibly 
other oxidized metabolites of all-irans-DRA. We showed that 
the same enzymes involved in the oxidation of ROL to RA are 
also involved in the oxidation of DROL to DRA as depicted in 
Scheme 1. All-irans-DROL and other more oxidized metabo­
lites occur naturally and represent a novel and potentially 
important pathway in the metabolism of vitamin A. This hy­
pothesis is supported by the unequivocal identification of all- 
irans-DROL and all-irans-DRA in Lrat-  /  -  mice gavaged with 
all-irans-ROL palmitate.
Characterization o f the Transactivation Activity of All-trans- 
DRA—All-irans-RA binding to RAR and 9-cis-RA binding to 
RAR or RXR can control the expression of genes containing 
RA-response element (RARE) sequences within their promoter 
region. RARE elements are composed of direct repeats (DR) of 
the canonical sequence PuG(G/T)TCA separated by one to five 
nucleotides. Activated RAR/RXR heterodimers can associate 
with RARE composed of DR separated by five nucleotides 
(DR5), which are found in the promoter region of many genes 
including the RARj3 gene (33).
We studied whether DRA could also control gene expression 
through RAR activation by using a DR5 RARE-reporter cell 
line. The F9 teratocarcinoma cell line expresses endogenous 
RAR and RXR and is exquisitely sensitive to the effects of RA. 
This cell line has been transfected with lacZ under the control 
of a minimal promoter and upstream DR5 elements (29). F9- 
RARE-/ocZ cells were treated with different doses of all- 
trans-RA or all-irans-DRA for 24 h, after which the cells were 
harvested, and the j3-galactosidase activity was evaluated by 
X-gal staining (Fig. 5, top panels). All-irans-DRA transactiva­
tion of DR5-induced j3-galactosidase expression was observed 
at higher concentrations than the equivalent effect produced by 
RA. All-irans-RA and all-irans-DRA induction activity was 
quantified by using the soluble substrate o-nitrophenyl j3-n- 
galactopyranoside. The colorless substrate was cleaved by 
j3-galactosidase to yellow colored o-nitrophenol, whose absorb­














Fig. 6. Activation of DR1 elem ents b y  all-frcms-DRA, all-trans- 
RA, and 9-e/s-RA. HEK-293S cells were transfected with a construct of 
lacZ under the control of a minimal promoter and five consecutive 
upstream DR1 elements. Top, HEK-293S cells were cotransfected with 
both DR1 -reporter construct and mouse RXR« under the control of the 
CMV promoter. The cells were then treated with the indicated levels of 
all-irans-RA, 9-c/s-RA, or all-irans-DRA for 48 h. The cells were har­
vested, and f!-galactosidase activity was assayed as described under 
“Materials and Methods.” Bottom, DR1-reporter transfected cells were 
treated with different doses of all-irans-RA, 9-c/s-RA, or all-irans-DRA 
in the absence of RXR for 48 h. The background f!-galactosidase activity 
in unstimulated cells is indicated by the dashed line in both upper and 
lower graphs. The cells were harvested, and f!-galactosidase activity 
was assayed as described under “Materials and Methods.” The experi­
ment was repeated twice with similar results.
5). All-froras-DRA induction of DR5 elements is much less effi­
cient than that of all-froras-RA. Induction of DR5 reporter cells 
with 1CT9 m all-froras-RA had a magnitude similar to the one 
obtained with 1CP7 m all-fra ras-DRA. The response measured in 
the linear part of the dose-response curve showed that all- 
trans-DRA is about 100-fold less effective than all-froras-RA in 
activating DR5-response elements.
RXR homodimers can be activated by 9-cis-RA (34), phytanic 
acid ( 35), docosahexanoic acid ( 36), and other unsaturated fatty 
acids ( 37). RXR homodimers can bind DR1 elements of hexameric 
motifs separated by a single base pair as found in the CRBP II 
promoter (38). We studied activation of RXR based on a DR1- 
reporter cell assay using HEK-293S cells with a construct of lacZ 
under the control of a minimal promoter and five consecutive 
upstream DR1 elements, which we termed pRXRE-BLUE. Be­
cause HEK-293S cells express little endogenous RXR, there is no 
induction of DR1 elements by 9-cis-RA in the absence of exoge­
nous RXR (Fig. 6, bottom graph). Thus, we cloned mouse RXRa 
and expressed it under the control of the CMV promoter in 
HEK-293S cells, which we cotransfected with pRXRE-BLUE. In 
our assay 9-cis-RA activates RXR-mediated transcription, 
whereas all-froras-DRA was a veiy weak RXR activator (Fig. 6, 
top graph). Even though all-£raras-RA does not bind RXR, we 
found that addition of all-froras-RA also resulted in robust induc­
tion of RXR homodimers in comparison with all-froras-DRA. This 
result could be a consequence of all-fraras-RA isomerization to 
9-cis-RA during the overnight incubation.
DISCUSSION
In this study we identify all-froras-DRA and other 13,14- 
dihydroretinoid metabolites in the tissues of Lrat— / — mice 
supplemented with ROL palmitate, and we demonstrate that 
all-froras-DRA can control gene expression in reporter cell as­
says. All-froras-DRA stimulated expression of a DR5-RARE re­
porter gene by activating RAR/RXR heterodimers in F9-RARE- 
lacZ cells. All-froras-DRA did not activate RXR homodimers in
HEK-293S cells cotransfected with a DRl-ZacZ reporter con­
struct and mouse RXRa. In combination with a previous report 
on the identification of all-froras-DROL as the product of RetSat 
(23), this study characterized the enzymatic pathway respon­
sible for the formation of all-froras-DRA from all-froras-ROL. 
Saturation of the C13^ 14 bond of all-froras-ROL by RetSat pro­
duces all-froras-DROL, which is oxidized to the corresponding 
retinaldehyde, all-froras-DRAL, by ADH-1 and possibly by SDR 
family RDHs present in the RPE. All-froras-DRAL is oxidized to 
all-froras-DRA by RALDH1^4. All-froras-DRA can be oxidized to 
all-froras-4-oxo-DRA in mice gavaged with all-froras-DROL and 
in vitro by cytochrome P450 enzymes CYP26A1, -Bl, and -Cl, 
suggesting a possible pathway for its degradation (Scheme 1). 
All the substrates and products of reactions and metabolites 
isolated from mouse tissues were identified by comparing their 
UV-visible absorbance spectra and chromatographic profile 
with authentic synthetic standards characterized by NMR and 
mass spectrometry. Contrary to a previous report indicating 
the conversion of 9-ds-RA to 9-cis-DRA (24), we found 110 evi­
dence of in vivo conversion of all-froras-RA into all-froras-DRA. 
Thus, all-froras-DRA can only be derived from oxidation of 
all-froras-DROL, and RetSat is the sole known enzyme respon­
sible for catalyzing the key step in all-froras-DRA formation. 
These findings indicate that saturation of all-froras-ROL by 
RetSat is an active and possibly important step in the metab­
olism of retinoids in vivo.
Synthesis and Degradation of All-trans-DRA—Many of the 
ADH and SDR families and some RALDHs are expressed in 
the retina and RPE (17, 39^43). We demonstrate in the 
current study that a pathway of conversion of all-froras-DROL 
into all-froras-DRA exists and is efficient in RPE microsomes 
(supplemental Fig. 10). This implies tha t all-froras-DRA syn­
thesis can occur in the same tissues where all-froras-RA syn­
thesis occurs and tha t all-froras-DRA could have a concentra­
tion gradient in different tissues. This gradient will be 
determined by the availability of synthetic and catabolic en­
zymes as well as the availability of primary substrate, i.e. 
all-trans -DROL.
RA bioavailability is tightly regulated by the balance be­
tween its biosynthesis and catabolism (44). The cytochrome 
P450-type enzymes, which include ubiquitously expressed 
CYP26A1, -Bl, and -Cl (19, 20, 22, 45), oxidize RA to 4-OH-RA, 
4-oxo-RA, 18-OH-RA, and 5,8-epoxy-RA. Thus, CYP26 enzymes 
are involved in limiting spatial and temporal levels of RA, and 
in concert with ADH, SDR, and RALDH they guard a desirable 
level of RA, protecting against fluctuations in the nutritional 
levels of ROL. As shown here, CYP26A1, -Bl, and -Cl enzymes 
also metabolize all-froras-DRA. This could also contribute to a 
temporal and spatial gradient of DRA in vivo.
Identification o f Chain-shortened ROL Metabolites—111 
this study we report the identification of an ROL metabolite 
that contains an alcohol functional group and is saturated at 
the C13^ 14 bond and chain-shortened at C-15. Chain-short­
ened ROL metabolites have been described in early studies 
that followed the fate of radioactive 14C-labeled RA or all- 
trans-ROL (46^48). One possible pathway for their synthesis 
could be through a-oxidation of all-froras-DRA as suggested 
previously by others (24). The C19-ROL metabolite could be 
the product of a reduced C 19-aldehyde intermediate pro­
duced during the a-oxidation of all-froras-DRA (equivalent to 
the pristanal intermediate of the phytanic acid degradation 
pathway). Only low amounts of C19-ROL were observed in 
L rat— / — mice supplemented with all-froras-DROL compared 
with the levels obtained in mice gavaged with all-froras-ROL 
palmitate. This discrepancy might be accounted for by the 















repertoire of enzymes than does all-iraras-DROL adminis­
tered by gavage. The definite pathway of synthesis of the 
C19-ROL could be established by using knock-out animal 
models deficient in specific enzymes of this pathway.
Potential Role o f 13,14-Dihydroretinoids in Vertebrate 
Physiology—Based on experiments using mice deficient in 
specific enzymes involved in retinoid metabolism, it was 
shown th a t ADH1 and RALDH1 are involved in a protection 
mechanism in response to pharmacological doses of ROL. 
A d h l - / -  and R a ld h l—/ — mice were much more sensitive to 
ROL-induced toxicity than their wild type counterparts (49, 
50). I t was proposed th a t conversion of ROL to RA protects 
against excess levels of dietary ROL. This idea is counterin­
tuitive considering the well known toxic effects of RA. Here 
we show th a t ADH1 and RALDH1 are also involved in DROL 
oxidation to DRA and th a t all-iroras-DRA is a much weaker 
activator of RAR- or RXR-mediated transcription compared 
with all-trans or 9-«s-RA. Thus, it is possible th a t saturation 
of the C13_14 bond of all-iroras-ROL could be the first step in 
a degradation pathway, which provides protection against 
pharmacological doses of all-iroras-ROL and circumvents the 
formation of RA. Our findings show th a t the combined 
amounts of hepatic DROL and DROL metabolites amount to 
less than one-third of the amount of hepatic all-iroras-RA at 
3 h post-gavage with 106 IU  ROL palmitate/kg body weight. 
This would suggest th a t saturation by RetSat is a rate-lim ­
iting reaction in the metabolic pathway.
Another possibility is tha t RetSat activity leads to produc­
tion of novel bioactive 13,14-dihydroretinoids. We identify 
all-iroras-DRA as an activator of RAR/RXR heterodimer-me­
diated transcription. The tissue concentration and transacti­
vation profile of all-iroras-DRA are both lower than those of 
all-iroras-RA. It is possible tha t all-iraras-DRA and other 
DROL metabolites could have im portant transactivation ac­
tivity in certain physiological circumstances. The local con­
centration of 13,14-dihydroretinoid ligand might reach 
higher levels as a result of being trapped by receptors or 
binding proteins. Given th a t the local concentration and 
binding affinity are sufficient, all-iraras-DRA could be an 
im portant endogenous ligand for RAR or possibly for other 
nuclear receptors. The finding th a t the same enzymes that 
were thought to act specifically in the formation of RA are 
also responsible for the formation of DRA has to be consid­
ered in attem pts to rescue with RA the phenotype of knock­
out animal models deficient in these enzymes. In one such 
example, Raldh2 — J — mouse embryos cannot be completely 
rescued by maternal RA supplementation and die prenatally 
(51). I t is interesting to speculate if  other retinoid metabo­
lites, including 13,14-dihydroretinoids, in addition to RAmay 
be necessary for a complete rescue of Raldh2 — /  -  embryos. 
The identification of the all-iroras-DRA metabolic pathway is 
the first step in this process, and more studies are necessary 
to establish the physiological role of DRA and other DROL 
metabolites in controlling gene expression.
In summary, we describe a new metabolic pathway for vita­
min A that leads to a new class of endogenous bioactive reti­
noids. We demonstrate that all-iroras-ROL saturation to all- 
iroras-DROL followed by oxidation to all-iraras-DRA occurs in 
vivo. All-iroras-DRA can activate transcription of reporter genes 
by binding RAR but does not bind RXR. The oxidative pathway 
of all-irons-DROL employs the same enzymes as that of all- 
iraras-ROL. We expect tha t these previously unknown metab­
olites will help us better understand the vital functions of 
retinoids in vertebrate physiology.
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